Idexx Laboratories Inc /De reports $1.22 billion revenue for quarter ended June 30, 2026, up 9.7%
Idexx Laboratories Inc /De reported revenue of $1.22 billion for the quarter ended June 30, 2026, an increase of 9.7% from the same quarter a year earlier ($1.11 billion).
For the same period it posted net income of $338.4 million, up 15.1%, or $4.27 per diluted share (3.63 a year earlier).
That is a net margin of 27.8%.
On Sanad's AAOIFI Standard 21 screen, Idexx Laboratories Inc /De is currently compliant: interest-bearing debt is 0.7% of market capitalisation (limit 30%), and impure income is 0.1% of revenue (limit 5%).
Is Idexx Laboratories Inc /De halal?
See the full AAOIFI screening of Idexx Laboratories Inc /De
See the full AAOIFI screening of Idexx Laboratories Inc /De
Source: 10-Q filed with the U.S. Securities and Exchange Commission on August 4, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.